TORONTO, Dec. 30, 2022 /CNW/ - Think Research Corporation
(TSXV: THNK) ("Think" or the "Company"), a company
focused on transforming healthcare through digital health software
solutions, today announced that it has issued an aggregate of
546,388 common shares (the "Common Shares") at the deemed
price of $0.36 to the former
shareholders of MDBriefCase Group Inc. (the "MDB
Shareholders").
As initially announced in Company's press release dated
January 18, 2021, the MDB
Shareholders are entitled to deferred consideration upon the
achievement of certain financial milestones during the two-year
period following closing of the sale of MDBriefCase Group Inc.,
such deferred consideration to be payable in Common Shares of the
Company. The Company and MDB Shareholders have mutually agreed that
the deferred consideration for the year ended December 31, 2021 shall be paid by the Company to
the Vendors in the form of cash and/or shares, at the option of the
Company, in two installments. This issuance represents payment for
the first 50% of the deferred consideration with the second 50%
payable on May 31, 2023.
About Think Research
Corporation
Think Research Corporation is an industry leader in delivering
knowledge-based digital health software solutions. The Company's
focused mission is to organize the world's health knowledge so
everyone gets the best care. Its evidence-based healthcare
technology solutions support the clinical decision-making process,
standardize care, to facilitate better health care outcomes. The
Company gathers, develops, and delivers knowledge-based solutions
globally to customers which typically includes enterprise clients,
hospitals, health regions, healthcare professionals, and / or
governments. The Company has gathered a significant amount of data
by building its repository of knowledge through its network and
group of companies, including acquired companies.
Think licenses its solutions to over 13,000 facilities for over
300,000 primary care, acute care, and long-term care doctors,
nurses and pharmacists that rely on the content and data provided
by Think to support their practices. Millions of patients and
residents annually receive better care due to the essential data
that Think produces, manages and delivers.
In addition, the Company collects and manages pharmaceutical and
clinical trial data via the BioPharma Services entity that Think
acquired on September 10, 2021.
BioPharma Services is a leading provider of bioequivalence and
Phase 1 clinical research services to pharmaceutical companies
globally. Think's other services include a network of digital-first
primary care clinics and medical clinics that provide elective
surgery. Visit: thinkresearch.com
For more information:
https://www.thinkresearch.com/ca/investors/
SOURCE Think Research Corporation